New cancer drug targets HER3 in advanced tumors
Disease control
Not yet recruiting
This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC